201 related articles for article (PubMed ID: 29503151)
1. Management-Based Structured Reporting of Posttreatment Glioma Response With the Brain Tumor Reporting and Data System.
Weinberg BD; Gore A; Shu HG; Olson JJ; Duszak R; Voloschin AD; Hoch MJ
J Am Coll Radiol; 2018 May; 15(5):767-771. PubMed ID: 29503151
[No Abstract] [Full Text] [Related]
2. Radiology: criteria for determining response to treatment and recurrence of high-grade gliomas.
Lucas J; Zada G
Neurosurg Clin N Am; 2012 Apr; 23(2):269-76, viii. PubMed ID: 22440870
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
[TBL] [Abstract][Full Text] [Related]
4. [Computed tomographic features of cerebral malignant glioma following treatment and regrowth. Growth patterns of recurrent tumors].
Sato I; Tanaka R; Takeda N; Suzuki Y; Hondo H
Neurol Med Chir (Tokyo); 1988 Nov; 28(11):1073-80. PubMed ID: 2466210
[No Abstract] [Full Text] [Related]
5. Imaging of intratumoral heterogeneity in high-grade glioma.
Hu LS; Hawkins-Daarud A; Wang L; Li J; Swanson KR
Cancer Lett; 2020 May; 477():97-106. PubMed ID: 32112907
[TBL] [Abstract][Full Text] [Related]
6. Advances in Magnetic Resonance and Positron Emission Tomography Imaging: Assessing Response in the Treatment of Low-Grade Glioma.
Kim MM; Lawrence TS; Cao Y
Semin Radiat Oncol; 2015 Jul; 25(3):172-80. PubMed ID: 26050587
[TBL] [Abstract][Full Text] [Related]
7. CXCL12 and CXCR4 as predictive biomarkers of glioma recurrence pattern after total resection.
Tang W; Wang X; Chen Y; Zhang J; Chen Y; Lin Z
Pathol Biol (Paris); 2015 Sep; 63(4-5):190-8. PubMed ID: 26277915
[TBL] [Abstract][Full Text] [Related]
8. Striking a Chord? Not a Typical Low-Grade Glioma.
McDermott DM; Singh SA
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):518-519. PubMed ID: 32976779
[No Abstract] [Full Text] [Related]
9. Posttreatment evaluation of central nervous system gliomas.
Shiroishi MS; Booker MT; Agarwal M; Jain N; Naghi I; Lerner A; Law M
Magn Reson Imaging Clin N Am; 2013 May; 21(2):241-68. PubMed ID: 23642552
[TBL] [Abstract][Full Text] [Related]
10. Metabolic deactivation of low-grade glioma during chemotherapy.
Roelcke U; Wyss M; Bärtschi E; Hofer S
J Neurol; 2007 May; 254(5):668-9. PubMed ID: 17410330
[No Abstract] [Full Text] [Related]
11. Low-grade Glioma, High Stakes Controversy-When and How to Treat in the Molecular Era?
Tom MC; Murphy ES
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):516-517. PubMed ID: 29893268
[No Abstract] [Full Text] [Related]
12. Local control of gliomas: the next best step--a good step?
Westphal M; Giese A
Front Radiat Ther Oncol; 1999; 33():214-26. PubMed ID: 10549491
[No Abstract] [Full Text] [Related]
13. Brain stem gliomas: therapeutic options at time of recurrence.
Rekate HL
Pediatr Neurosurg; 1996 Oct; 25(4):220. PubMed ID: 9293549
[No Abstract] [Full Text] [Related]
14. 11C-MET PET/CT and advanced MRI in the evaluation of tumor recurrence in high-grade gliomas.
D'Souza MM; Sharma R; Jaimini A; Panwar P; Saw S; Kaur P; Mondal A; Mishra A; Tripathi RP
Clin Nucl Med; 2014 Sep; 39(9):791-8. PubMed ID: 25036022
[TBL] [Abstract][Full Text] [Related]
15. Scintigraphic assessment of recurrent glioma with focus on proliferation.
Alexiou GA; Tsiouris S; Polyzoidis KS; Kyritsis AP; Fotopoulos AD
Nucl Med Commun; 2008 Sep; 29(9):840-1. PubMed ID: 18677216
[No Abstract] [Full Text] [Related]
16. Diagnostic validity and reliability of BT-RADS in the management of recurrent high-grade glioma.
Ebaid NY; Ahmed RN; Assy MM; Amin MI; Alaa Eldin AM; Alsowey AM; Abdelhay RM
J Neuroradiol; 2024 Jun; 51(4):101190. PubMed ID: 38492800
[TBL] [Abstract][Full Text] [Related]
17. Radiosensitization of high-grade gliomas through induced hyperthermia: Review of clinical experience and the potential role of MR-guided focused ultrasound.
Schneider CS; Woodworth GF; Vujaskovic Z; Mishra MV
Radiother Oncol; 2020 Jan; 142():43-51. PubMed ID: 31431370
[TBL] [Abstract][Full Text] [Related]
18. Molecular imaging and advanced MRI findings following immunotherapy in patients with brain tumors.
Galldiks N; Lohmann P; Werner JM; Ceccon G; Fink GR; Langen KJ
Expert Rev Anticancer Ther; 2020 Jan; 20(1):9-15. PubMed ID: 31842635
[No Abstract] [Full Text] [Related]
19. Posttreatment high-grade glioma: usefulness of peak height position with semiquantitative MR perfusion histogram analysis in an entire contrast-enhanced lesion for predicting volume fraction of recurrence.
Kim HS; Kim JH; Kim SH; Cho KG; Kim SY
Radiology; 2010 Sep; 256(3):906-15. PubMed ID: 20634429
[TBL] [Abstract][Full Text] [Related]
20. Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma.
Vos MJ; Hoekstra OS; Barkhof F; Berkhof J; Heimans JJ; van Groeningen CJ; Vandertop WP; Slotman BJ; Postma TJ
J Clin Oncol; 2003 Oct; 21(19):3559-65. PubMed ID: 12913097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
